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Background: Tamoxifen, an agonist of estrogen receptor, is widely prescribed for the prevention and long-term
treatment of breast cancer. A side effect of tamoxifen is fatty liver, which increases the risk for non-alcoholic fatty
liver disease. Prevention of tamoxifen-induced fatty liver has the potential to improve the safety of long-term
tamoxifen usage.
Methods: Uridine, a pyrimidine nucleoside with reported protective effects against drug-induced fatty liver, was
co-administered with tamoxifen in C57BL/6J mice. Liver lipid levels were evaluated with lipid visualization using
coherent anti-Stokes Raman scatting (CARS) microscopy, biochemical assay measurement of triacylglyceride (TAG),
and liquid chromatography coupled with mass spectrometry (LC-MS) measurement of membrane phospholipid.
Blood TAG and cholesterol levels were measured. Mitochondrial respiration of primary hepatocytes in the presence
of tamoxifen and/or uridine was evaluated by measuring oxygen consumption rate with an extracellular flux
analyzer. Liver protein lysine acetylation profiles were evaluated with 1D and 2D Western blots. In addition, the
relationship between endogenous uridine levels, fatty liver, and tamoxifen administration was evaluated in
transgenic mice UPase1−/−and UPase1-TG.
Results: Uridine co-administration prevented tamoxifen-induced liver lipid droplet accumulation in mice. The most
prominent effect of uridine co-administration with tamoxifen was the stimulation of liver membrane phospholipid
biosynthesis. Uridine had no protective effect against tamoxifen-induced impairment to mitochondrial respiration of
primary hepatocytes or liver TAG and cholesterol export. Uridine had no effect on tamoxifen-induced changes to
liver protein acetylation profile. Transgenic mice UPase1−/−with increased pyrimidine salvage activity were protected
against tamoxifen-induced liver lipid droplet accumulation. In contrast, UPase1-TG mice with increased pyrimidine
catabolism activity had intrinsic liver lipid droplet accumulation, which was aggravated following tamoxifen
administration.
Conclusion: Uridine co-administration was effective at preventing tamoxifen-induced liver lipid droplet accumulation.
The ability of uridine to prevent tamoxifen-induced fatty liver appeared to depend on the pyrimidine salvage pathway,
which promotes biosynthesis of membrane phospholipid.
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Tamoxifen is an effective drug widely used for the treat-
ment of estrogen receptor-positive breast cancer [1].
Women taking tamoxifen from 5 to 10 years exhibit
reduced risks of breast cancer recurrence and mortality
[2,3]. While generally well-tolerated, tamoxifen is known
to induce fatty liver in 43% of women within the first
2 years of treatment [4-6]. Fatty liver is an established risk
factor for non-alcoholic fatty liver disease (NAFLD) [7].
Prolonged tamoxifen treatment increases the risk of
NAFLD, particularly in women with pre-existing meta-
bolic condition [8].
The mechanism underlying tamoxifen-induced fatty
liver is a topic of active investigation. Evidence from
several independent research groups supports tamoxifen-
induced impairment of mitochondrial fatty acid oxidation
(FAO) as a primary cause of lipid accumulation in the liver
[9-11]. Co-administration of tetradecylthioacetic acid,
which improves mitochondrial and peroxisomal FAO, pre-
vents tamoxifen-induced fatty liver [12]. Tamoxifen also
inhibits hepatic triacylglyceride secretion leading to liverFigure 1 Uridine salvage and membrane phospholipid biosynthesis. Dlipid accumulation [10,11]. Therapeutic intervention to
prevent tamoxifen-induced fatty liver condition has the
potential to improve the safety of long-term tamoxifen
usage for breast cancer treatment.
Uridine, a pyrimidine nucleoside, has been shown to
prevent fatty liver condition induced by several drugs with
unrelated therapeutic usages and acting mechanisms
[13,14]. Uridine could be salvaged into pyrimidine nucleo-
tides or catabolized into uracil and subsequently β-alanine
and acetyl-CoA (Figure 1) [15]. Homeostatic regulation of
uridine is controlled by uridine phosphorylase, an enzyme
that catalyzes the reversible phosphorylitic conversion of
uridine to uracil [16]. Genetic knock-out of uridine phos-
phorylase in UPase1−/−mice elevates tissues and plasma
levels of uridine [17]; whereas, transgenic overexpression
of uridine phosphorylase in UPase1-TG mice depletes tis-
sues and plasma levels of uridine [18]. The liver is actively
regulating plasma uridine level by continuously degrading
plasma uridine and replacing it with de novo uridine
synthesis [19]. The interaction between liver uridine
homeostasis and lipid metabolism has been reported [18].ashed arrows indicate multiple enzymatic reactions.
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determined. Consequently, therapeutic potential of uridine
for treatment of fatty liver condition has not been realized.
In this study, we examine the effects of uridine co-
administration with tamoxifen on liver lipid content in
control C57BL/6J and transgenic UPase1−/−and UPase1-
TG mice. Specifically, we examine the contribution of
pyrimidine salvage and catabolism pathways to the bio-
logical activity of uridine. We aim to explore therapeutic
potential of uridine for the prevention of drug-induced




All animal studies were performed with the ethical
approval of the Animal Care and Use Committees at
Nevada Cancer Institute, Desert Research Institute, and
Touro University Nevada. All experiments conducted on
animals were in compliance with the guidelines of the U.S.
Office of Laboratory Animal Welfare of the National
Institutes of Health and the Public Health Service Policy
on Humane Care and Use of Laboratory Animals.
Experimental animals
Three mice strains were used, C57BL/6J or wildtype
mice (Jackson Laboratories, Bar Harbor, ME), UPase1-
TG mice with ubiquitous genetic knock-in of uridine
phosphorylase 1 [18], and UPase1−/−mice with ubiqui-
tous genetic knock-out of uridine phosphorylase 1 [17].
Transgenic mice described in this study have been
deposited into the Mutant Mouse Regional Resource
Centers supported by the National Institutes of Health.
The MMRRC strains are now known as B6;129-Upp1tm1Gp/
Mmucd (037119-UCD) for UPase1−/−mice and B6; FVB-Gt
(ROSA) 26Sortm1.1(CAG-Upp1)Gp/Mmucd (037120-UCD) for
UPase1-TG mice. All mice used were female at 10–12
weeks of age with average bodyweight of approximately 20
grams.
Study design
All mice were randomly divided into groups of 4 or 5
mice per cage and housed in a controlled environment
with an average temperature of 22°C, a 12 hours of light
and 12 hours of dark cycle, and with ad libitum access
to food and water. For control C57BL/6J mice, 36 mice
were randomly divided into 4 experimental groups of 9
mice per group: control diet (C57BL/6J), diet supple-
mented with uridine (C57BL/6J + U), diet supplemented
with tamoxifen (C57BL/6J + Tmx), and diet supplemented
with both tamoxifen and uridine (C57BL/6J + Tmx +U).
For transgenic UPase1−/−and UPase1-TG mice, 18 mice
per strain were randomly divided into the following 4
experimental groups of 9 mice per group: UPase1−/−miceon control diet (UPase1−/−), UPase1−/−mice on tamoxifen-
supplemented diet, UPase1-TG mice on control diet
(UPase1-TG), and UPase1-TG mice on tamoxifen-supple
mented diet. In addition, 6 C57BL/6J mice were used for
primary hepatocyte collection for bioenergetics experi-
ments. The number of mice per experimental group was
chosen to ensure that data obtained were statistically
significant.
Experimental procedures
Control mice were fed with PicoLab Mouse Diet ground
pellets (Cat. No. 5058, LabDiet, Brentwood, MO) that
provide 4.6 kcal/g and consist of 22% protein and 9% fat.
The lipid composition includes cholesterol (200 ppm),
linoleic acid (2.32%), linolenic acid (0.21%), arachidonic
acid (0.02%), and omega-3 fatty acid (0.32%). The total
saturated and monounsaturated fatty acids are 2.72%
and 2.88%, respectively. For mice receiving uridine sup-
plementation alone, uridine was thoroughly mixed with
ground pellets with a dosage of 400 mg/kg/day. For mice
receiving tamoxifen treatment alone, tamoxifen was
thoroughly mixed with ground pellets with a dosage of
200 mg/kg/day. For mice receiving both uridine and tam-
oxifen, uridine and tamoxifen were thoroughly mixed with
ground pellets with a dosage of 400 mg/kg/day and
200 mg/kg/day, respectively. Mice were placed on control
or supplemented diets for 5 days prior to terminal liver
and blood samples collection. All samples were collected
in early mornings. Blood samples were collected via the
tail veins while mice were under anesthesia with isoflur-
ane. Liver tissues were collected following cardiac perfu-
sion under deep anesthesia with isoflurane. Cardiac
perfusion was necessary to ensure collection of pure liver
tissues devoid of blood and plasma contaminants. Mice
were anaesthetized and incisions were made from the ab-
domen up to the torso. Diaphragms were severed and 22
gauge needles were inserted into the left ventricles. Phos-
phate buffered saline (PBS) was used as the perfusate. Ap-
proximately 50–100 ml of PBS was flushed through each
mouse from the left ventricle and exited through the inci-
sion made to the right atrium. Following the perfusion
procedure, liver tissues were collected for immediate
usage or frozen in liquid nitrogen for future usage.
CARS imaging of liver tissues
A home-built CARS microscope was used to image lipid
using CH2 vibrational frequency at 2851 cm
−1 as described
previously [20]. Approximately 31 frames were taken along
the vertical axis at 1-micron increment for volumetric
evaluation of liver lipid content. Liver lipid level was the
square root of resonant CARS signal intensity, which is the
difference between total CARS signal intensity and CARS
signal intensity arising from cellular membrane and non-
resonant signal [21-23]. Liver lipid level was normalized to
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strains or treatment conditions. Quantitative analysis of
liver lipid level was performed using the NIH ImageJ soft-
ware. Liver was perfused with PBS prior to collection. Liver
tissues were sliced into 200-micron thick sections, trans-
ferred into glass-bottom chambered slides, overlaid with
200 microliter of 1% agarose, and imaged with CARS mi-
croscopy. On average, 9 imaging volumes were analyzed
with CARS microscopy per liver sample. The xyz dimen-
sions of each analysis volume were 167 μm× 167 μm×
30 μm. Nine liver samples from nine mice were used for
CARS imaging analysis per animal group.
Biochemical measurement of liver triacylglyceride (TAG)
Liver samples of equal weight were used for chloroform/
methanol total lipid extraction. TAG was determined
using the commercial TAG quantitation kit (Cat. No.
10010303, Cayman Chemical, Ann Arbor, MI) according
to manufacturer’s protocol and normalized with liver tis-
sue weight. Nine liver samples from nine mice were used
for biochemical TAG measurement per animal group.
1D Western blots
Total liver protein extracts were separated on 10% SDS-
PAGE gels, transferred to nitrocellulose membranes, in-
cubated first with primary antibodies against proteins of
interest and then with secondary antibodies conjugated
with horseradish peroxidase (Cat. No. 31460, Thermo
Scientific, Rockford, IL). Membrane was developed with
enhanced chemiluminescence reagents (Cat. No. 34075,
Thermo Scientific), stripped, and re-incubated with anti
bodies against β-actin for evaluation of loading controls.
Primary antibodies against acetylated lysine and β-actin
were from Cell Signaling (Cat. No. 9441 & 4967, Danvers,
MA).
2D Western blots
2DWestern blots were performed by Kendrick Laboratories
(Madison, WI). Approximately 500 μg of protein from each
liver tissue was loaded per gel. Proteins were separated
using isoelectric focusing (IEF) in the first dimension and
SDS polyacrylamide gel electrophoresis (SDS-PAGE) in the
second dimension. Primary and secondary antibodies were
the same as in 1D Western blot. Molecular weight stan-
dards were: myosin (220,000), phosphorylase A (94,000),
catalase (60,000), actin (43,000) carbonic anhydrase
(29,000) and lysozyme (14,000) (Sigma Chemical Co.,
St. Louis, MO).
Bioenergetics of primary hepatocytes
Immediately after isolation, primary hepatocytes were
plated into 24-well plates at a density of 1 × 105 cell per
well. Plating media was consisted of DMEM with 25 mM
glucose, 2 mM glutamine, 10% FBS, 0.1 mM sodiumpyruvate, 1% Pen/Strep, and 1 mM HEPES at pH 7.4. At
4 hours after plating, primary hepatocytes were incubated
for 24 hours with either uridine alone, tamoxifen alone, or
a combination of tamoxifen and uridine depending on the
treatment condition. The final concentration used for uri-
dine was 100 μM and tamoxifen was 10 μM. At 90 minutes
prior to assaying, plating media was replaced with Cellular
Assay Solution consisting of DMEM, 25 mM glucose,
2 mM glutamine, 1 mM sodium pyruvate and adjusted to
pH 7.2 with 25 mM of MOPS. Bioenergetics of primary he-
patocytes were determined using the XF Cell Mito Stress
Test Kit and a XF24-3 Analyzer (Seahorse Bioscience,
North Billerica, MA) following manufacturer’s suggested
protocols and published protocols [24]. Bioenergetics ex-
periments were performed at the UCLA’s Cellular Bioener-
getics Core Facilities. At least 24 repeated measurements
were performed per experimental condition. Final concen-
trations of oligomycin, FCCP, rotenone, and myxothiazol
were 1 μg/ml, 1 μM, 0.1 μM, and 2 μM, respectively. Oxy-
gen consumption rates were reported as absolute values
(pmol O2 consumed per minute) on a per-unit of protein
basis, where average protein concentration per well was
normalized to 1.
Clinical blood lipid analysis
Analysis of blood lipid level (TAG, cholesterol, HDL, and
LDL) were performed by Research Animal Diagnostic
Laboratory (RADIL, Columbia, MO) on terminally col-
lected blood samples of 6 mice per animal group. HDL
and LDL were determined via direct measurement.
Measurement of phospholipid with LC-MS
Total liver lipid extracts of 6 mice per animal group
were sent to Kansas Lipidomics Research Center (Kansas
State University, Manhattan, KS) for LC-MS analysis of
phospholipid species. Concentrations of phospholipid
are expressed as nmol per mg of dried liver lipid weight.
Statistical analysis
Data were presented as average values ± standard devia-
tions. Statistical analysis was performed using Excel’s
paired Student’s t-test and analysis of variance (ANOVA)
functions. Statistical significance was set at p ≤ 0.05.
Results and discussion
The effects of tamoxifen treatment on liver lipid content
were evaluated in C57BL/6J mice. Daily dosage of 200 mil-
ligrams tamoxifen per kilogram bodyweight was chosen
for mice to reproduce equivalent dosage administered in
humans after adjusting for differences in energy metabol-
ism and pharmacokinetics between species [25]. Following
5 days of tamoxifen treatment, mice lost up to 5% of
bodyweight. Traditional histopathology analysis does not
have sufficient sensitivity to analyze mild hepatic
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ment for 5 days [11,21]. Therefore, collected liver tissues
were examined with CARS microscopy, a highly sensitive
method for lipid visualization [22,23,26], to evaluate liver
lipid content. Liver tissues of untreated control mice and
mice treated with uridine did not exhibit any intracellular
lipid accumulation (Figure 2A). In contrast, liver tissues of
mice treated with tamoxifen had significant intracellular
lipid droplet accumulation, which could be classified as
microvesicular steatosis [27]. Quantitative analysis of liver
lipid level using CARS signal intensity revealed that tam-
oxifen treatment increased intracellular liver lipid level by
76% (Figure 2B). Surprisingly, uridine co-administration
completely prevented tamoxifen-induced hepatic steatosis
(Figure 2A,B). Data obtained with CARS microscopy were
corroborated with biochemical measurements of liver tria-
cylglyceride content (Figure 2C). Oil Red O histology was
also performed on all liver tissue samples. However, ORO
histology was unable to detect mild hepatic microvesicularFigure 2 Uridine prevents tamoxifen-induced fatty liver. (A) CARS ima
6J liver tissues as a function of uridine and/or tamoxifen treatment. (B) Liver lip
(TAG) levels determined with biochemical assays. Error bars are standard deviat
indicates p-value < 0.05 versus untreated control mice. Double asterisks (gray) isteatosis associated with tamoxifen treatment (data not
shown). The insensitivity of ORO histology to detect mild
microvesicular steatosis had been described in the litera-
ture [21,28-30]. It is important to point out that while uri-
dine co-administration completely suppressed tamoxifen-
induced hepatic microvesicular steatosis, it had no impact
on tamoxifen-induced weight loss in mice.
Uridine has the ability to modulate liver protein acetyl-
ation profile [14,18]. Uridine catabolism produces acetyl-
CoA, which is a donor substrate for protein acetylation [18].
Uridine supplementation also elevates liver NAD+/NADH
ratio, which alters the activity of NAD+-dependent deacety-
lases [18]. Liver protein acetylation is highly correlated to
energy metabolism [31,32]. To determine whether uridine
prevented tamoxifen-induced fatty liver by modulating pro-
tein acetylation profile, 1D Western blots using antibodies
against acetylated lysine residues were performed on total
liver extracts (Figure 3A). Tamoxifen treatment in-
creased acetylation of a protein band with molecularges (upper panels) and 3D surface plots of lipid distribution of C57BL/
id level determined with CARS image analysis. (C) Liver triacylglyceride
ion values across 9 mice analyzed per animal group. Single asterisk (black)
ndicate p-value < 0.05 versus C57BL/6J mice treated with tamoxifen.
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with tamoxifen had no effect on the acetylation state of
this protein band.
Next, 2D Western blots were employed for high
resolution evaluation of liver protein acetylation profiles
(Figure 3B). Consistent with 1D Western blots, 2D Western
blots revealed that tamoxifen treatment induced acetylation
of a protein spot with molecular weight of 80 kD (Figure 3B,
box with dashed line). Also consistent with 1D Western
blot, uridine co-administration with tamoxifen could not
prevent the effect of tamoxifen-induced hyper-acetylation
of this 80 kD protein spot. Overall, when uridine was
co-administered with tamoxifen, it had no impact on
liver protein acetylation profile. Therefore, it was un-
likely that uridine prevented tamoxifen-induced fatty
liver by modulating liver protein acetylation profiles.
Tamoxifen treatment is associated with impaired
mitochondrial respiration [9,11]. To determine whether uri-
dine co-administration could prevent the inhibitory effects
of tamoxifen on mitochondrial respiration, primary hepato-
cyte cell cultures were employed. An Extracellular Flux
Analyzer was employed to measure 5 key parameters of
cellular bioenergetics: basal respiration, non-mitochondrial
respiration, ATP production, proton leak, and maximal res-
piration using a previously described protocol [24]. Consist-
ent with the literature, tamoxifen treatment severely
reduced oxygen consumption rates in primary hepatocytes
for all parameters evaluated (Figure 4A). Uridine adminis-
tration by itself had no effect on mitochondrial respirationFigure 3 Effects of uridine and tamoxifen on liver protein acetylation pro
β-actin serves as a loading control. (B) 2D Western blot analysis of liver protein
locations of a protein band at 80 kD whose acetylation level increases with tamof primary hepatocytes. Surprisingly, uridine co-
administration could not prevent tamoxifen-induced im-
pairment to mitochondrial respiration in primary hepato-
cytes. Thus, it was unlikely that uridine co-administration
prevented fatty liver by restoring mitochondrial function
impaired by tamoxifen.
Tamoxifen treatment is associated with reduced liver
secretion of TAG and cholesterol [10,11]. To determine
if uridine co-administration with tamoxifen could im-
prove liver secretion of TAG and cholesterol, blood lipid
profiles were evaluated (Figure 4B). Consistent with the
literature, tamoxifen treatment caused reduction of
blood TAG and cholesterol levels. Uridine treatment by
itself had no effect on blood TAG and cholesterol levels.
Neither could uridine co-administration prevent tamo
xifen-induced reduction of blood TAG and cholesterol
levels. Thus, there was no evidence to support a role of
uridine in reversing tamoxifen-induced suppression of
liver secretion of TAG and cholesterol.
Salvage of uridine to cytidine triphosphate promotes
phospholipid biosynthesis in the presence of phospho-
choline and diacylglycerol [15,33]. To determine if there
was a role for uridine salvage in the prevention of
tamoxifen-induced fatty liver, lipidomics profiling of liver
phospholipid with LC-MS was carried out (Figure 4C,
Table 1). When administered individually, both uridine
and tamoxifen increased the levels of many liver
phospholipid species. When administered together, uri-
dine and tamoxifen further increased the levels of manyfile. (A) 1D Western blot analysis of liver protein lysine acetylation profile.
lysine acetylation profile. Box with dashed black lines highlights the
oxifen treatment.
Figure 4 Effects of uridine and tamoxifen on hepatocyte mitochondrial respiration, blood lipid level, and liver phospholipid level.
(A) Oxygen consumption rate (OCR) of primary hepatocytes measured with an Extracellular Flux Analyzer. Error bars are standard deviation values
across 24 repeated measurements per experimental condition. (B) Blood levels of triacylglyceride, cholesterol, high-density lipoprotein (HDL), and
low-density lipoprotein (LDL) determined via direct measurements. (C) Changes in selective phospholipid species as a function of uridine and/or tamoxifen
treatment. Lysophosphotidylcholine (LPC); phosphotidylcholine (PC); sphingomyelin (SM) & dihydrosphingomyelin (DSM); lysophosphoethanolamine (LPE);
phosphoethanolamine (PE); ether-linked phosphoethanoamine (ePE); phosphatidylserine (PS). Error bars are standard deviation values across 6 mice
analyzed per animal group. Asterisks indicate p-value < 0.05 versus untreated control mice.
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phospholipid species were sphingomyelin, phosphatidyl-
serine, and phosphoethanolamine, where uridine co-
administration with tamoxifen increased their levels by
as much as 80%. The lipidomics data suggested that uri-
dine could prevent tamoxifen-induced fatty liver by pro-
moting membrane phospholipid biosynthesis.
To further evaluate the relationship between pyrimidine
salvage pathway and the prevention of tamoxifen-induced
fatty liver, UPase1−/−and UPase1-TG mice were employed.
UPase1−/−mice have elevated liver and circulating uridine
concentration due to genetic knock-out of a gene encod-
ing for uridine phosphorylase 1, an enzyme that catalyzes
uridine catabolism [17]. On average, UPase1−/−mice haveliver and plasma concentration of 42.8 μM and 7.2 μM, re-
spectively; whereas, C57BL/6J mice have liver and plasma
concentration of 6.8 μM and 1.5 μM, respectively [34]. For
UPase1−/−strain, liver tissues of untreated control mice
were devoid of intracellular lipid droplet (Figure 5A-C).
Tamoxifen treatment of UPase1−/−mice did not lead to
intracellular lipid droplet accumulation in the liver tissues.
On the other hand, UPase1-TG mice have depleted liver
and circulating uridine concentration due to genetic
knock-in of a gene encoding for for uridine phosphorylase
1 [18]. On average, UPase1-TG mice have liver and plasma
uridine concentration of 0.5 μM and 0.08 μM, respectively.
For UPase1-TG strain, liver tissues of untreated control
mice were already exhibiting microvesicular steatosis
Table 1 Liver phospholipid species quantified with LC-MS
Phospholipid species (nmol/mg) C57BL/6J C57BL/6J + U C57BL/6J + Tmx C57BL/6J + Tmx + U
Lysophosphotidylcholine 6.7 ± 0.7 7.1 ± 0.3 7.4 ± 0.4 8.6 ± 0.8*
Phosphotidylcholine 380.5 ± 51 486.8 ± 20* 421.9 ± 30.6 495.1 ± 39.6*
Sphingomyelin & dihydrosphingomyelin 29.1 ± 3.7 40.0 ± 2.8* 50.3 ± 3.9* 50.2 ± 3.7*
Ether-linked phosphotidylcholine 18.9 ± 2.2 18.5 ± 0.6 21.2 ± 1.4 22.5 ± 2.1
Lysophosphoethanolamine 1.9 ± 0.1 2.3 ± 0.26 2.1 ± 0.2 2.6 ± 2.1
Phosphoethanolamine 105.5 ± 8.9 140.1 ± 8.8* 149.2 ± 8.3* 165.6 ± 8.9*
Phosphoethanoamine-ceramide 0.01 ± 0.01 0.01 ± 0.01 0.016 ± 0.005 0.027 ± 0.013
Ether-linked Phosphoethanoamine 4.0 ± 0.4 4.5 ± 0.3 4.5 ± 0.3 5.6 ± 0.4*
Phosphatidylinositol 51.2 ± 6.9 60.0 ± 7.1 46.9 ± 3.7 58.4 ± 6.2
Phosphatidylserine 15.4 ± 0.8 22.3 ± 1.1* 25.4 ± 1.3* 28.2 ± 1.3*
Ether-linked phosphatidylserine 0.2 ± 0.03 0.3 ± 0.03* 0.36 ± 0.017* 0.4 ± 0.04*
Phosphatidic acid 19.9 ± 2.3 23.2 ± 2.4 15.2 ± 1.7 21.2 ± 1.4
Phosphatidylglycerol 27.2 ± 3.1 29.9 ± 2.7 33.0 ± 2.1 29.7 ± 2.2
Asterisks indicate p-value <0.05 versus untreated control.
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increased liver lipid content by approximately 20% com-
pared to untreated control UPase1-TG mice. Hence,
UPase1−/−mice, which had increased pyrimidine salvage
activity [17], were protected against tamoxifen-induced
fatty liver. In contrast, UPase1-TG mice, which had
increased uridine catabolism activity [18], were susceptible
to further liver lipid accumulation following tamoxifen
treatment.Figure 5 Increased uridine salvage protects liver against tamoxifen-indu
C57BL/6J and transgenic UPase1−/−and UPase1-TG mice as a function of tamo
analysis. (C) Liver triacylglyceride (TAG) levels determined with biochemical as
animal group. Single asterisk (black) indicates p-value < 0.05 versus untreated
C57BL/6J mice treated with tamoxifen.Conclusions
In this study, we report that uridine co-administration is
effective at completely preventing intracellular lipid
droplet accumulation in the liver tissues of mice treated
with tamoxifen. To examine the roles of uridine in the
prevention of tamoxifen-induced fatty liver, several as-
pects of liver energy metabolism perturbed by tamoxifen
were evaluated. Tamoxifen administration was associated
with an increased in acetylation of a protein band at 80ced lipid accumulation. (A) CARS images of liver tissues of wildtype
xifen treatment. (B) Liver lipid level determined with CARS image
says. Error bars are standard deviation values across 9 mice analyzed per
control mice. Double asterisks (gray) indicate p-value < 0.05 versus
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both of these tamoxifen-induced effects could not be
reversed by uridine co-administration. Neither could
uridine prevent tamoxifen-induced reduction in blood
TAG and cholesterol levels. Surprisingly, both uridine
and tamoxifen when administered alone and together
increased membrane phospholipid biosynthesis. The
synthesis of phosphatidylcholine (PC), the key component
of phospholipid, was dependent on the availability of diac-
ylglycerol (DAG) and cytidine diphosphocholine (CDPC)
(Figure 1) [33]. It is possible that tamoxifen-induced lipid
accumulation in liver tissues made TAG and DAG to be
readily available for PC synthesis. Uridine salvage into
CTP promoted CDPC synthesis, which together with
DAG availability stimulated PC synthesis. Transgenic mice
UPase1−/−with increased uridine salvage into CTP were
protected against tamoxifen-induced fatty liver. In con-
trast, UPase1-TG mice with overt catabolism of uridine
had intrinsic fatty liver phenotype, which was aggravated
following tamoxifen treatment. In summary, uridine co-
administration was able to prevent tamoxifen-induced
intracellular lipid droplet accumulation, but not able to
prevent other side effects associated with tamoxifen treat-
ment such as impaired mitochondrial respiration and
reduced TAG and cholesterol export. A plausible means
that uridine prevented tamoxifen-induced fatty liver was
via the pyrimidine salvage pathway, which channeled
neutral lipid into phospholipid biosynthesis and reduced
cytoplasmic lipid accumulation.
A previous study on the anti-proliferative effect of
tamoxifen in human MCF-7 breast cancer cells proposed
that tamoxifen prevented DNA synthesis by blocking
uridine transport, thus, inhibiting the pyrimidine salvage
pathway [35]. In our study, C57BL/6J mice with dietary
uridine supplementation or UPase1−/−mice with elevated
endogenous uridine levels both had enhanced pyrimidine
salvage activity [17]. Both mice strains were resistant to
tamoxifen-induced fatty liver; however, they exhibited
weight loss following tamoxifen treatment. In addition,
uridine supplementation in primary hepatocyte cultures
could not prevent tamoxifen-induced impairment to
mitochondrial respiration. Our observation indicates
that tamoxifen exert inhibitory effects beyond the
pyrimidine salvage pathway. Indeed, tamoxifen has
been shown to directly intercalate mitochondrial DNA
(mtDNA) and impair mtDNA synthesis and mitochon-
drial respiration [11]. It is unlikely that uridine can pre-
vent the interaction of cationic tamoxifen with mtDNA,
hence, its inability to suppress the inhibitory effects of
tamoxifen on mitochondrial function.
The balance between purine and pyrimidine nucleotides
is critical for the maintenance of genomic stability and
regulation. A surge in uridine concentration subsequently
leads to a rise in pyrimidine nucleotides and perturbs thebalance of the nucleotide pool [15]. Therefore, an adaptive
mechanism must be in place to cope with excessive
uridine concentration. In rodents, most tissues rely on the
plasma for uridine supply [36]. The circulating uridine
concentration is tightly regulated by the liver, where
plasma uridine is cleared in a single pass and replaced
with newly synthesized uridine [19]. Hence, the liver
effectively serves as a regulator of uridine homeostasis.
Rapid clearance of uridine in the liver involves both
uridine salvage and catabolism, where uridine metabolites
affect other cellular processes in a non-specific manner.
Multi-targeted effects are evident by the ability of uridine
to prevent fatty liver caused by different drugs with vastly
different acting mechanisms [13,14]. Multi-targeted effects
pose a challenge for precise therapeutic targeting using
uridine. However, uridine homeostasis is regulated by
uridine phosphorylase [16]. The enzymatic activity of
uridine phosphorylase has been modulated by pharma-
ceutical compounds to prevent toxicity associated with 5-
fluorouracil treatment of cancer [37]. Modulation of uridine
phosphorylase enzymatic activity is a possible means to
achieve precise therapeutic targeting of uridine for the
prevention of drug-induced fatty liver.
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